AVTX Avalo Therapeutics Inc

Price (delayed)

$19.45

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.37

Enterprise value

$957.67M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 22

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders. The company is advancing its clinical-stage ...

Highlights
Avalo Therapeutics's quick ratio has soared by 168% from the previous quarter and by 55% YoY
The EPS has soared by 57% YoY and by 20% from the previous quarter
AVTX's net income has plunged by 117% YoY and by 18% from the previous quarter
The company's gross profit has shrunk by 94% YoY

Key stats

What are the main financial stats of AVTX

AVTX stock price

How has the Avalo Therapeutics stock price performed over time
Intraday
-0.51%
1 week
4.01%
1 month
2.86%
1 year
114.33%
YTD
7.1%
QTD
5.25%

Financial performance

How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$59,000
Gross profit
$59,000
Operating income
-$91.36M
Net income
-$100.33M
Gross margin
100%
Net margin
-170,055.9%
AVTX's net income has plunged by 117% YoY and by 18% from the previous quarter
The company's gross profit has shrunk by 94% YoY
AVTX's revenue has shrunk by 87% YoY
Avalo Therapeutics's gross margin has plunged by 59% YoY

Price vs fundamentals

How does AVTX's price correlate with its fundamentals

Growth

What is Avalo Therapeutics's growth rate over time

Valuation

What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
2.28
P/S
14,373.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16,231.73
The EPS has soared by 57% YoY and by 20% from the previous quarter
AVTX's P/B is 29% below its last 4 quarters average of 3.2
The P/S is 142% higher than the last 4 quarters average of 5949.5
AVTX's revenue has shrunk by 87% YoY

Efficiency

How efficient is Avalo Therapeutics business performance
The return on invested capital has surged by 98% year-on-year and by 44% since the previous quarter
The ROE rose by 41% since the previous quarter but it has declined by 20% year-on-year
Avalo Therapeutics's ROA has decreased by 34% YoY but it has increased by 33% from the previous quarter
The ROS has contracted by 18% from the previous quarter

Dividends

What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVTX.

Financial health

How did Avalo Therapeutics financials performed over time
Avalo Therapeutics's quick ratio has soared by 168% from the previous quarter and by 55% YoY
AVTX's current ratio has surged by 152% since the previous quarter and by 55% year-on-year
The debt is 100% smaller than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.